Go Pro

BTIG Research's Rating of Serina Therapeutics on 9/10/2026

On September 10, 2026, BTIG Research updated its outlook on Serina Therapeutics (NYSEAMERICAN:SER) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
9/16/2026
Coinbase Global, Inc. stock logo
COIN
Coinbase Global
Reiterated Rating
9/16/2026
American Bitcoin Corp. stock logo
ABTC
American Bitcoin
Initiated Coverage
9/16/2026
McDonald's Corporation stock logo
MCD
McDonald's
Reiterated Rating
9/16/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Reiterated Rating
9/16/2026
On Holding AG stock logo
ONON
ON
Reiterated Rating
9/16/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Boost Price Target
More Ratings From BTIG Research